TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention

Inclusion Criteria: * Patients with breast cancer, expressing HER2-NEU (score +++ in ICH or ++ and amplification on FISH or CISH, SISH) * Visceral metastasis, only or multiple * First line metastasis treatment by Trastuzumab in association with chemotherapy * Good general conditions: OMS=\<2 or Karnofsky \>=70% * Age \> 18 years and \< 70 years * Life expectancy \>=3 mois * No Trastuzumab since more of 6 months * No cerebral metastasis (MRI) * Efficacy contraception for women with genital capacities * Consent signed by the patient Exclusion Criteria * Contraindication to IRM * Psychiatric decease * Prior cerebral radiotherapy, * Geographical constraint, compromising the fallow of patients * Infectious or other serious pathology, likely to stop the treatment * Positive serology (HIV, hBC, hBS) * Inclusion in an other clinical trial or in the 4 weeks before th inclusion * Pregnant or breastfeeding women